COYA (Coya Therapeutics) Shares Outstanding (EOP): 23.46 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

COYA Coya Therapeutics Inc COYA
49 GF Score
Price $4.39
GF Value $6.54
Valuation Significantly Undervalued
View Full Analysis

What is Coya Therapeutics Shares Outstanding (EOP)?

Coya Therapeutics COYA -3.10% 49 Shares Outstanding (EOP) is 23.46 Mil as of Jun. 2026. GuruFocus rates COYA with a GF Score™ of 49/100 and a GF Value™ of $6.54 (Significantly Undervalued).

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Coya Therapeutics's shares outstanding for the quarter that ended in Jun. 2026 was 23.46 Mil.

Coya Therapeutics's quarterly shares outstanding increased from Mar. 2026 (23.46 Mil) to Jun. 2026 (23.46 Mil). It means Coya Therapeutics issued new shares from Mar. 2026 to Jun. 2026 .

Coya Therapeutics's annual shares outstanding increased from Dec. 2024 (16.71 Mil) to Dec. 2025 (20.93 Mil). It means Coya Therapeutics issued new shares from Dec. 2024 to Dec. 2025 .


Coya Therapeutics  (NAS:COYA) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Coya Therapeutics Shares Outstanding (EOP) Related Terms


Coya Therapeutics Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Coya Therapeutics's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Coya Therapeutics Shares Outstanding (EOP) Chart

Coya Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shares Outstanding (EOP)
Get a 7-Day Free Trial 9.68 9.68 14.41 16.71 20.93

Coya Therapeutics Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.73 16.74 20.93 23.46 23.46

COYA vs ONCY, GUTS, SEER: Shares Outstanding (EOP) Comparison

For the Biotechnology subindustry, Coya Therapeutics's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Coya Therapeutics Shares Outstanding (EOP) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coya Therapeutics's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Coya Therapeutics's Shares Outstanding (EOP) falls into.


COYA
49GF Score
Coya Therapeutics Inc COYA
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Coya Therapeutics Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 23.46 Mil mean?
Coya Therapeutics (COYA) has a Shares Outstanding (EOP) of 23.46 Mil as of Jun. 2026. The total shares a company has outstanding, at period-end. View historical data on Coya Therapeutics and its competitors.
Is Coya Therapeutics' Shares Outstanding (EOP) too high?
Coya Therapeutics' current Shares Outstanding (EOP) is 23.46 Mil. Overall, Coya Therapeutics has a GF Score™ of 49/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Coya Therapeutics' Shares Outstanding (EOP) compare to ONCY and GUTS?
Coya Therapeutics' Shares Outstanding (EOP) of 23.46 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Coya Therapeutics and its competitors. Coya Therapeutics's current Shares Outstanding (EOP) is 23.46 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coya Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Coya Therapeutics (COYA) is currently considered Significantly Undervalued. The stock's GF Value™ is $6.54, compared to a current price of $4.39 — trading 32.9% below its estimated fair value. The current Shares Outstanding (EOP) is 23.46 Mil. Coya Therapeutics' overall GF Score™ is 49/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Coya Therapeutics (COYA), the current Shares Outstanding (EOP) is 23.46 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Coya Therapeutics (COYA) Overvalued in 2026?

Based on GuruFocus' analysis, Coya Therapeutics stock appears to be undervalued. The current stock price of $4.39 is trading 32.9% below its estimated GF Value™ of $6.54. GuruFocus considers Coya Therapeutics to be Significantly Undervalued.

Key valuation signals for COYA:

  • Shares Outstanding (EOP): 23.46 Mil
  • GF Value™: $6.54 vs. price of $4.39 (32.9% below fair value)
  • GF Score™: 49/100

No single metric tells the full story. See the COYA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Coya Therapeutics Business Description

Address 5850 San Felipe Street, Suite 500, Houston, TX, USA, 77057
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.
49GF Score

Get the complete analysis for COYA

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.39
Price
$6.54
GF Value